Premium
Azilsartan, New Angiotensin II Type 1 Receptor Blocker, Would Suppress Morning Surge in Hypertension
Author(s) -
Isegawa Kengo,
Hirooka Yoshitaka,
Kishi Takuya,
Sunagawa Kenji
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.927.3
Subject(s) - candesartan , medicine , blood pressure , morning , angiotensin ii , angiotensin receptor , circadian rhythm , pharmacology , endocrinology , cardiology
Background Recent investigations on circadian variations of blood pressure have shown that the suppression of morning surge is crucial in optimal management of hypertension. The pressure surge is often observed in the neurohormonal transitional phase from the rest to active phase. Azilsartan (AZL), a new angiotensin II type 1 receptor blocker (ARB), is a powerful and long‐acting antihypertensive agent. We examined if AZL suppress the elevation of blood pressure from the light‐rest to dark‐active phase in spontaneously hypertensive rats. Methods and Results SHR were divided into three groups, treated at 5:00 for 28 days with orally administered azilsartan (AZL; 1mg/kg/day), candesartan (CAN; 1mg/kg/day), or vehicle (VEH). Telemetric mean arterial pressures (MAP) for 24 hours were similarly lower in AZL and CAN, than vehicle (AZL 108±4, CAN 116±7, VEH 134±5 mmHg, p<0.01). Both in the light‐rest (from 6:00 AM to 6:00 PM) and dark‐active phase (from 6:00 PM to 6:00 AM), MAP were similarly lower in AZL and CAN than in VEH. However, the changes in MAP between the last 4 hours in light‐rest phase and the first 2 hours in dark‐active phase were significantly lower in AZL than in CAN (−2±2 vs. 3±1 mmHg, p<0.05). Conclusion AZL is capable of lowering the elevation of blood pressure from the rest to active phase, indicating that AZL may benefit hypertensive patients with pressure surge in the early morning.